Related Experiment Video

Updated: Sep 15, 2025

Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors
09:45

Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors

Published on: January 1, 2017

10.9K

Reprogramming of peripheral blood mononuclear cells from a patient with hypophosphatasia to generate iPSC line

Abhay Srivastava1, Niketa Sareen1, Cheryl Rockman-Greenberg2

  • 1Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Regenerative Medicine Program, Department of Physiology and Pathophysiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba.

Stem Cell Research
|July 13, 2025
PubMed

Insights

Researchers developed a new cell line from a patient with perinatal hypophosphatasia (HPP), a rare genetic disorder affecting bones and teeth. This cell line will aid in studying HPP

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Cell Biology

Background:

  • Hypophosphatasia (HPP) is a rare inherited metabolic disorder impacting bones and teeth.
  • HPP presents across a spectrum of ages, from prenatal to adult onset.
  • The genetic basis of HPP involves mutations in the ALPL gene, encoding tissue-nonspecific alkaline phosphatase.

Purpose of the Study:

  • To establish and characterize a new human cell line derived from a patient with perinatal hypophosphatasia.
  • To utilize this cell line for investigating the molecular and cellular mechanisms underlying HPP caused by a specific ALPL mutation.
  • To employ the cell line as a platform for screening potential therapeutic strategies for HPP.

Main Methods:

  • Generation of a novel cell line (UOMi011-A) from a 7-year-old female patient with perinatal HPP.
  • Genetic analysis confirming a homozygous c.1001G>A (p.Gly334Asp) mutation in the ALPL gene in the patient.
  • Cell line characterization for future studies on HPP pathogenesis and therapeutic development.

Main Results:

  • Successful establishment of a new human cell line (UOMi011-A) from a perinatal HPP patient.
  • Confirmation of the homozygous ALPL gene mutation (c.1001G>A, p.Gly334Asp) in the cell line.
  • The cell line represents a valuable resource for HPP research.

Conclusions:

  • The newly established UOMi011-A cell line provides a critical tool for studying hypophosphatasia.
  • This resource will facilitate research into the genotype-phenotype correlations and disease mechanisms of HPP.
  • The cell line is poised to accelerate the discovery and testing of novel HPP therapies.

More Related Videos

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector12:03

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

26.8K
Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors08:14

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Published on: October 28, 2014

12.9K

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
24.4K